Patents by Inventor Ralph W. Niven

Ralph W. Niven has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of Simple Amino Acids to Form Porous Particles
    Publication number: 20170354602
    Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.
    Type: Application
    Filed: January 26, 2017
    Publication date: December 14, 2017
    Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
  • Use of Simple Amino Acids to Form Porous Particles
    Publication number: 20160287517
    Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.
    Type: Application
    Filed: April 7, 2016
    Publication date: October 6, 2016
    Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
  • Use of simple amino acids to form porous particles
    Patent number: 9333174
    Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: May 10, 2016
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
  • USE OF SIMPLE AMINO ACIDS TO FORM POROUS PARTICLES
    Publication number: 20130071440
    Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.
    Type: Application
    Filed: August 17, 2012
    Publication date: March 21, 2013
    Applicant: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
  • Use of simple amino acids to form porous particles
    Patent number: 8268358
    Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: September 18, 2012
    Assignee: Civitas Therapeutics, Inc.
    Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
  • Use of Simple Amino Acids to Form Porous Particles
    Publication number: 20120020887
    Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.
    Type: Application
    Filed: January 20, 2011
    Publication date: January 26, 2012
    Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
  • USE OF SIMPLE AMINO ACIDS TO FORM POROUS PARTICLES
    Publication number: 20080160098
    Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.
    Type: Application
    Filed: October 17, 2007
    Publication date: July 3, 2008
    Applicant: Advanced Inhalation Research, Inc.
    Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
  • USE OF SIMPLE AMINO ACIDS TO FORM POROUS PARTICLES
    Publication number: 20080160092
    Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.
    Type: Application
    Filed: October 17, 2007
    Publication date: July 3, 2008
    Applicant: Advanced Inhalation Research, Inc.
    Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
  • Use of simple amino acids to form porous particles
    Patent number: 7252840
    Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: August 7, 2007
    Assignee: Advanced Inhalation Research, Inc.
    Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
  • Use of simple amino acids to form porous particles during spray drying
    Patent number: 6586008
    Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: July 1, 2003
    Assignee: Advanced Inhalation Research, Inc.
    Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
  • Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
    Publication number: 20020010318
    Abstract: The present invention relates to the pulmonary administration of a therapeutic protein by means of powdered pharmaceutical compositions suitable for inhalation therapy. In particular the invention relates to dry powder formulations of secretory leukocyte protease inhibitor (SLPI) for pulmonary delivery. Exemplary pharmaceutical compositions contain SLPI and a pharmaceutically acceptable carrier in the form of a dry powder which is typically less than about 10% by weight water. About 50% to 95% by mass of the powder comprises particles or agglomerates of particles having a diameter within the range of from about 1.0 microns to about 8 microns, with a mass median diameter ranging from about 3.0 microns to about 6 microns.
    Type: Application
    Filed: June 29, 2001
    Publication date: January 24, 2002
    Applicant: Amgen, Inc.
    Inventors: Ralph W. Niven, Clifford D. Wright, Byeong S. Chang
  • Cationic lipid formulation delivering nucleic acid to peritoneal tumors
    Patent number: 6271209
    Abstract: Methods of transfecting cells in vivo, including tumor cells in the peritoneal cavity are provided. Related lipid:nucleic acid formulations adapted to transfecting cells in the peritoneal cavity are provided. Assays, including high-throughput assays for screening lipid:nucleic acids are also provided.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: August 7, 2001
    Assignee: Valentis, Inc.
    Inventors: Janet G. Smith, Ralph W. Niven, Yilin Zhang
  • CATIONIC LIPID FORMULATION DELIVERING NUCLEIC ACID TO PERITONEAL TUMORS
    Publication number: 20010008772
    Abstract: Methods of transfecting cells in vivo, including tumor cells in the peritoneal cavity are provided. Related lipid:nucleic acid formulations adapted to transfecting cells in the peritoneal cavity are provided. Assays, including high-throughput assays for screening lipid:nucleic acids are also provided.
    Type: Application
    Filed: April 1, 1999
    Publication date: July 19, 2001
    Inventors: JANET G. SMITH, RALPH W. NIVEN, YILIN ZHANG
  • SECRETORY LEUKOCYTE PROTEASE INHIBITOR DRY POWDER PHARMACEUTICAL COMPOSITIONS
    Publication number: 20010006939
    Abstract: The present invention relates to the pulmonary administration of a therapeutic protein by means of powdered pharmaceutical compositions suitable for inhalation therapy. In particular the invention relates to dry powder formulations of secretory leukocyte protease inhibitor (SLPI) for pulmonary delivery. Exemplary pharmaceutical compositions contain SLPI and a pharmaceutically acceptable carrier in the form of a dry powder which is typically less than about 10% by weight water. About 50% to 95% by mass of the powder comprises particles or agglomerates of particles having a diameter within the range of from about 1.0 microns to about 8 microns, with a mass median diameter ranging from about 3.0 microns to about 6 microns.
    Type: Application
    Filed: October 3, 1997
    Publication date: July 5, 2001
    Inventors: RALPH W. NIVEN, CLIFFORD D. WRIGHT, BYEONG S. CHANG